XOMA Corp

NASDAQ: XOMA    
Share price (5/17/24): $25.51    
Market cap (5/17/24): $297 million
Search in Documents
Key Exhibits
External Links
2 XOMA Corp Expert Interviews, now on BamSEC.
 Powered by Tegus.

Underwriting Agreements Filter

EX-1.1
from 8-K 33 pages 1,400,000 Depositary Shares XOMA Corporation Each Representing 1/1000th of a Share of 8.375% Series B Cumulative Perpetual Preferred Stock Underwriting Agreement
12/34/56
EX-1.1
from 8-K 32 pages 880,000 Shares XOMA Corporation 8.625% Series a Cumulative Perpetual Preferred Stock Underwriting Agreement
12/34/56
EX-1.1
from 8-K 33 pages 8,097,165 Shares and Warrants to Purchase 8,097,165 Shares XOMA Corporation Common Stock Placement Agent Agreement
12/34/56
EX-1.1
from 8-K 27 pages 9,500,000 Shares XOMA Corporation
12/34/56
EX-1.1
from 8-K 32 pages 7,596,685 Shares XOMA Corporation Common Stock Underwriting Agreement
12/34/56
EX-1.1
from 8-K 28 pages 13,333,333 Shares XOMA Corporation Common Stock Underwriting Agreement
12/34/56
EX-1.1
from 8-K 37 pages [Underwriting Agreement] 29,669,154 Shares Warrants to Purchase 14,834,577 Shares XOMA Corporation Common Stock ($0.0075 Par Value) Equity Underwriting Agreement
12/34/56
EX-1.2A
from POS AM 2 pages Amendment No. 1 to at Market Issuance Sales Agreement
12/34/56
EX-1.2
from S-3 38 pages At Market Issuance Sales Agreement
12/34/56
EX-1
from 8-K 2 pages XOMA Receives Anticipated Deficiency Notice From NASDAQ
12/34/56
EX-1
from 8-K 2 pages XOMA Announces $6 Million Antibody Discovery Collaboration With Arana Therapeutics
12/34/56
EX-1
from 8-K 1 page FDA Statement
12/34/56
EX-1
from 8-K 2 pages Press Release European Medicines Agency Recommends Suspension of the Marketing Authorisa- Tion of Raptiva
12/34/56
EX-1
from 8-K 2 pages XOMA and Takeda Expand Collaboration ###
12/34/56
EX-1
from 8-K 2 pages XOMA Updates Guidance for 2008 Royalty Income From EX-U.S. Lucentis(r) Sales Expected to Continue Through 2014
12/34/56
EX-1
from 8-K 2 pages XOMA Announces Workforce Reduction
12/34/56
EX-1
from 8-K 2 pages XOMA Appoints Fred Kurland as Chief Financial Officer
12/34/56
EX-1
from 8-K 2 pages XOMA Appoints John Varian to Board of Directors
12/34/56
EX-1
from 8-K 2 pages FDA Approves Updated Labeling for Psoriasis Drug Raptiva Safety Concerns Drove Labeling Changes
12/34/56
EX-1
from 8-K 2 pages News Release
12/34/56